-+ 0.00%
-+ 0.00%
-+ 0.00%

Harmony Biosciences to present Phase 3 ARGUS extension data for EPX-100 in Dravet syndrome

PUBT·04/16/2026 12:07:11
Listen to the news
Harmony Biosciences to present Phase 3 ARGUS extension data for EPX-100 in Dravet syndrome
  • Harmony Biosciences scheduled an encore presentation of open-label extension data from its Phase 3 ARGUS trial of EPX-100 (clemizole hydrochloride) in Dravet syndrome at American Academy of Neurology 2026.
  • Results were already presented previously, with the next presentation set for April 22, 2026.
  • Update is expected to focus on preliminary longer-term experience from ongoing treatment, including how participants are doing over time.
  • Trial remains in enrollment, keeping EPX-100 in active late-stage development for Dravet syndrome.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604160805BIZWIRE_USPR_____20260416_BW023008) on April 16, 2026, and is solely responsible for the information contained therein.